Bepirovirsen (Hibsago)
To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy
In two phase 3 trials of 1834 adults with noncirrhotic chronic HBV on NA therapy, 24 weeks of bepirovirsen vs placebo gave functional cure at week 72 in 20% vs none (B-Well 1) and 19% vs none (B-Well 2). Grade ≥3 adverse events: 16% vs 3%. RCT · phase 3 · n = 1,834 · N Engl J Med · 2026
Secondary analysis of the phase IIb B-Clear trial in chronic hepatitis B: bepirovirsen binding-site SNPs were found at baseline in 7% (22/309) of sequenced participants, who had numerically smaller HBsAg falls; 18% (4/22) still had transient HBsAg loss. Secondary analysis · phase 2 · n = 309 · J Hepatol · 2026